MINSTRY-SCINCE-ICT-FUTUR
17.5.2017 09:02:11 CEST | Business Wire | Press release
31 promising Korean startups are attending TNW Conference Europe 2017 (hereafter “the Conference”) to be held May 18-19, 2017, in Amsterdam, Netherlands.
31 Promising startups of Korea will showcase advanced technologies such as Fintech based on blockchain, nano new materials, eco-friendly products, IoT and software service to the European market.
Ministry of Science, ICT and Future Planning (hereafter “MSIP”), Ministry of Culture, Sports & Tourism and Small and Medium Business Administration of the Korean government are making joint efforts in backing tech startups to advance into the European market under the name of K-Startup.
Mr. Koh Kyeongmo, Deputy Minister for Creative Economy Coordination in MSIP showed high expectations for the Conference in that it will trigger promotion of Korean startups’ tech capabilities on the global stage and attract substantial investment in the future.
TNW Conference Europe 2017
This is the largest tech conference in Europe having been initiated from 2006 and it consists of programs including workshops, tailored networking events for startups and exhibitions. It is expected to attract about 20,000 participants and 4,000 companies who are tech investors, accelerators and startups from over 100 countries.
The Korean government will increase the support for Korean tech startups pioneering into the European market by utilizing the venue of the Conference.
Korea in TNW Conference
In the Conference, the Korean government is operating K-Startup Pavilion which displays products and services from various fields such as iris recognition devices and solutions, drones with one-handed controllers, seed packages and portable hydro-power generators.
In particular, the Korean government will cohost Investor Dinner with TNW, thereby fostering networking of global investors. In the venue, around 80 promising investors handpicked by TNW along with some Korean startups participate.
Furthermore, 7 Korean startups are advancing to the semi-final round of competition which guarantees them the chance to pitch in Arena. In the competitions, Korean startups’ innovative products will be promoted and the startups will compete to be award-winners.
31 Promising Startups of Korea
Major Korean startups will take part in the Conference. For example, Smart Study , a kids-content startup having exceeded 15.5m dollars in sales as of 2016 will attend the event. Studio XID , a software startup of which its service is used by global companies such as Google, Facebook, Baidu and Alipay will also participate. For detailed information on best Korean startups, please visit here or watch K-Startup Show reel.
- Smart Study: www.smartstudy.co.kr
- Studio XID: www.protopie.io
- KOREA STARTUPS: http://thewelcome.ipdisk.co.kr/publist/VOL1/guest/Korea%20Startup%20IR%20Report%20Edition.pdf
- K-Startup Show reel: http://thewelcome.ipdisk.co.kr:80/publist/VOL1/guest/K_Startup_TNW%20Showreel.mp4
View source version on businesswire.com: http://www.businesswire.com/news/home/20170517005049/en/
Contact:
Ministry of Science, ICT and Future Planning
Yang Yunay, +82 2 2110
2086
Deputy Director
yunay@korea.kr
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release
Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release
Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom